Global Hypopharyngeal Cancer Diagnostics Market Size (2023 - 2030)

The market for hypopharyngeal cancer diagnostics was valued at USD 2024.33 million in 2022, and it is anticipated to increase even more, with a CAGR of 7.22% from 2023 - 2030, to reach USD 3535.80 million by 2030. This market's outstanding rise can be linked to the development of the healthcare field, particularly the therapeutics field for cancer treatments.

Industry Overview:

Abnormal growth of cancer cells in the hypopharynx, a part of the lower throat, is called hypopharyngeal carcinoma. Behind the voice box and immediately above the esophageal intake in the lower neck and throat is where the hypopharynx is located. The bulk of these cancers (almost 95%) is squamous cell carcinomas, which are typically caused by smoking. However, other, more uncommon malignancies in this area can also develop and are typically not caused by smoking. The hypopharynx will be seen by your head and neck surgeon utilizing a quick office technique called flexible fiberoptic endoscopy. To aid in identifying tumor masses involving the hypopharynx, a tiny flexible scope is introduced into the nose. To ensure that the patient is comfortable and pain-free throughout the treatment, a local anesthetic is administered through the nose. To more accurately describe the tumor's extent, additional imaging tests (such as CT, MRI, or PET scans) could be required. The next step is typically a biopsy under general anesthesia in the operating room to confirm the diagnosis and get a better look at the tumor.

The tumor's size and if it has spread to other areas of the body will affect the available treatments. Depending on the size of the tumor, it may involve any or a mix of them, including surgery, radiation therapy, chemotherapy, and immunotherapy drugs that can stimulate the immune system to attack cancer. The optimum treatment plan is created for each patient individually using a team-based approach involving surgeons, radiation oncologists, medical oncologists, speech-language pathologists, and others to manage the tumor and promote the best quality of life possible following treatment. A sore throat and earache are indicators of hypopharyngeal carcinoma. A lump in the neck, painful or challenging swallowing, or a change in voice are some more signs.

COVID-19 impact on the Hypopharyngeal Cancer Diagnostics Market

Significantly detrimental consequences of the COVID-19 pandemic on business have included strict government rules, statewide lockdowns, an increase in infection rates, a decline in patient visits to hospitals and clinics, and a scarcity of medical professionals and healthcare employees. The COVID-19 pandemic has probably hit the most susceptible patient populations and those who need urgent access to medical care, including cancer patients. The purpose of this study was to evaluate how COVID-19 affected the early detection and treatment of Hypopharyngeal Cancer. Different groups of incident cancer patients have been managed differently as a result of the COVID-19 pandemic, with older patients, patients who were treated predominantly surgically, and patients with fewer comorbidities being most affected. These patients may experience worse oncological outcomes as a result of missing and delayed diagnoses. Concerns have been raised concerning a significant rise in preventable cancer mortality shortly as a result of COVID-19's impact on the referral, diagnosis, and treatment of cancer patients worldwide. The observed decreases in the number of cases are presumably the result of national and municipal restrictions, recommendations for patient management during several pandemic waves, changes in health-seeking behavior, and the impression that hospitals are high-risk places for COVID-19 transmission risk.

MARKET DRIVERS:

The growing Number of Clinical Trials is fostering market expansion.

The number of clinical trials for Hypopharyngeal cancer has greatly increased as a result of the growing research and development efforts devoted to the creation of various types of treatments. Up to this point, about 2957 clinical trials have been started for Hypopharyngeal cancer. About 52 clinical trials for Hypopharyngeal cancer were started worldwide in 2021. This figure is anticipated to rise in the upcoming years, encouraging market expansion throughout that time.

The market is estimated to grow as a result of rising applications for magnetic resonance imaging and MRI that is AI-enabled.

The use of magnetic resonance imaging (MRI) for the detection and diagnosis of breast cancer has seen significant breakthroughs. Contrast-enhanced magnetic resonance imaging (MRI) is useful in the diagnostic evaluation of female patients who present with abnormal mammograms or other clinical findings. In patients who have been diagnosed with a single illness, magnetic resonance imaging can find mammogram-occult multifocal cancer. Researchers are using machine learning to enhance images from MRI scanners in artificial intelligence-enabled MRI. The accuracy of artificial intelligence (AI) devices in correctly interpreting radiological findings are roughly 95%. Therefore, the expansion of MRI and MRI powered by artificial intelligence is being fueled by the rising applications of these technologies.

MARKET RESTRAINTS:

The hypopharyngeal cancer diagnostics market is hindered by a lack of sensitivity and specificity.

Any test that is intended to be used for cancer screening, diagnosis, or monitoring must have sufficient specificity and sensitivity to be effective. Cancer diagnostics must be precise to screen out healthy people and sensitive enough to find even the smallest tumors in the body. Currently, more than 1 million prostate biopsies are performed in the United States, the majority of which are repeat or needless procedures are done to make sure that no cancer patient is overlooked. It is a result of the non-specific PSA test being used for prostate cancer screening. The American Cancer Society and the American Urologic Association advise PSA testing for yearly cancer screening. However, due to a lack of data about the PSA test's specificity and its value in lowering morbidity or mortality, the National Cancer Institute, the American College of Physicians, and the U.S. Preventive Services Task Force do not recommend it. For the diagnosis of each kind of cancer, it is necessary to develop precise and sensitive biomarkers that may be used for population-wide screening. Therefore, it is anticipated that until particular and highly sensitive diagnostic tests are introduced to the market, the growth of the cancer diagnostics market will be significantly impacted.

HYPOPHARYNGEAL CANCER DIAGNOSTICS MARKET REPORT COVERAGE:

This research report on the Hypopharyngeal Cancer Diagnostics Market has been segmented and sub-segmented based on methods, application, and region.

Hypopharyngeal Cancer Diagnostics Market - By Methods

• Biopsy

• bone marrow biopsy
• needle biopsy
• endoscopic biopsy

• Endoscopy

• Bronchoscopy
• Colonoscopy
• Sigmoidoscopy
• Colposcopy
• others

• Imaging

• MRI scan
• PET scan
• CT scan
• Mammography
• ultrasound

• Tumor Biomarker Tests

• PSA Tests
• CTC Tests
• AFP Tests
• CA 19-9
• CA 125
• EGFR
• HER2
• CEA
• BRCA
• KRAS
• ALK

Imaging diagnostics are more popular than other diagnostic techniques because of their non-invasive features. Additionally, as technology develops, new imaging modalities and their combinations are being used more frequently around the world. Due to the rising incidence of cancer, image diagnostics is anticipated to maintain its leadership position in hypopharyngeal cancer diagnostics over the forecast period.

Hypopharyngeal Cancer Diagnostics Market - By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

In 2021, Europe was the second-largest market for hypopharyngeal cancer diagnostics, trailing North America. In 2021, North America accounted for a sizable portion of the global market for hypopharyngeal cancer diagnostics. This can be ascribed to the country's rising cancer occurrence as well as the country's well-established healthcare infrastructure and effective reimbursement system. According to the American Cancer Society, in 2021, there will be an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States. In the United States, there were reportedly 16.9 million cancer survivors as of January 2021. Up to 2030, there are estimated to be 22.2 million cancer survivors.

Hypopharyngeal Cancer Diagnostics Market Share by Company

1. Eli Lilly and Company
2. Bristol Myers Squibb Company
3. Sanofi S.A.
4. Merck & Co., Inc.
5. Pfizer Inc
6. AbbVie Inc.
7. Bayer AG
8. F. Hoffmann-La Roche Ltd.
9. Fresenius Medical Care AG & Co. KGaA
10. Sun Pharmaceutical Industries Ltd.
11. Teva Pharmaceutical Industries Limited
12. AstraZeneca Plc.
13. Astellas Pharma Inc.
14. AB Science SA
15. Boston Biomedical, Inc.

NOTABLE HAPPENINGS IN THE HYPOPHARYNGEAL CANCER DIAGNOSTICS MARKET IN THE RECENT PAST:

• Product Launch: The uPath PD-L1 (SP263) image analysis for non-small cell lung cancer, an automated digital pathology algorithm, was introduced by F. Hoffmann-La Roche Ltd. in July 2020.